Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Benchmarking a large network against national data can surface actionable gaps in dialysis delivery. We compared 2024 outcomes from DaVita Brazil clinics with the Brazilian Society of Nephrology (SBN) census 2024.
Cross-sectional analysis of aggregated 2024 data. Samples: DaVita (n=19,741 patients; 100 units) and SBN (n=76,946). Denominators: total patients for modality/adequacy; extracorporeal dialysis (HD+HDF) for vascular access. Proportions were compared with two-sided tests of two independent proportions (α=0.05). We report p<0.05 only for pre-specified, clinically relevant comparisons: HDF%, short-term CVC%, graft%, Kt/V<1.2%, and Hb<10%.
Modality mix. DaVita adopted HDF more widely than SBN: 12.3% vs 7.1% (p<0.05). HD shares were 83.4% vs 87.3%, PD 4.4% vs 5.6% (descriptive).
Vascular access (HD+HDF). DaVita vs SBN: AVF 64% vs 65% (descriptive); tunneled CVC 24% vs 23% (descriptive); short-term CVC 2% vs 8% (p<0.05); graft 10% vs 4% (p<0.05). Within-network trend 2021→2024 showed a fall in short-term CVC (6%→2%) and rise in AVF (60%→64%).
Adequacy/quality (non-conformity). DaVita showed lower underdialysis: Kt/V<1.2: 12% vs 24% (p<0.05), and fewer patients with anemia below target: Hb<10 g/dL: 27% vs 31% (p<0.05). Other markers were descriptive: albumin<3.5 g/dL 6% vs 10%; P>5.5 mg/dL 33% vs 33%; PTH>600 pg/mL 24% vs 21%; K≥6 mEq/L 20% vs 19%.
Baseline diagnoses (descriptive). Hypertension 31% vs 29%; diabetes 28% vs 29%; glomerulonephritis 8% vs 7%; polycystic kidney disease 4% vs 4%; undefined etiology 15% vs 19%.
In 2024, DaVita Brazil demonstrated greater HDF uptake, substantially fewer short-term catheters, and higher graft use than the national benchmark, alongside better adequacy (lower Kt/V<1.2) and fewer patients with Hb<10 g/dL. Priorities include sustaining the low short-term catheter rate while closing the small gaps in AVF and tunneled CVC mix, and targeted mineral-bone and potassium management. Findings support focused access-governance and adequacy bundles that are scalable in mixed public–private settings.
